Certara Products - Simcyp Archives | Certara

On-Demand Webinar

Leveraging the full potential of PBPK models to accelerate drug development

Explore how Novartis applies PBPK modeling in drug development using Simcyp to support regulatory decisions,…

CertaraMarch 20, 2026

Blog

What are Common Bioequivalence Study Mistakes?

Learn about the most common bioequivalence study mistakes drug developers make and the differences between…

CertaraMarch 20, 2026

Blog

ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug Development

With the release of the draft ICH M15 guidance, MIDD is no longer optional -…

CertaraMarch 18, 2026

Conference

Discovery & Development Europe 2026

CertaraMarch 13, 2026

Announcement

Certara Expands Simcyp® Simulator to Streamline Regulatory Submissions and Internal Efficiencies

Discover how the Simcyp Simulator’s PBPK models can streamlines drug development and reduces the number…

CertaraMarch 5, 2026

Blog

What is Simcyp Discovery and How Does it Support Drug Discovery?

Learn how Simcyp helps in drug discovery, supporting compound selection, first-in-human PK prediction, early DDI…

CertaraMarch 3, 2026

Press Release

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

Novartis used PBPK modeling for therapeutic regulatory success. They used model simulations to replace clinical…

CertaraMarch 3, 2026

Conference

Marbach DDI Workshop 2026

CertaraFebruary 26, 2026

Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Danielle PillsburyFebruary 23, 2026

Webinar

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

CertaraFebruary 23, 2026

© 2026 Certara. All Rights Reserved. | Legal | Privacy policy